AB Science: reduced first-half losses

(CercleFinance.com) - AB Science has reported a net loss of 4.
38 million euros for the first half of 2024, down from nearly 10.4 million a year earlier, and an operating deficit down 59.5% to 3.58 million at June 30, 2024.

The biopharmaceutical company's research and development costs fell by 65.5% to 2.56 million euros, reflecting the implementation of its strategy of seeking partnerships for the continued clinical development of masitinib.

AB Science recently carried out a capital increase of five million euros through the issue of 5,368,725 new ordinary shares (to which warrants are attached), a transaction subscribed by qualified European investors.

Copyright (c) 2024 CercleFinance.com. All rights reserved.